Use of liraglutide or semaglutide therapy does not increase risk for thyroid cancer among patients with type 2 diabetes or obesity.

GLP-1RA therapy significantly reduces the risk for new-onset heart failure in patients with T2D or obesity, regardless of weight loss.

Primary hyperparathyroidism is associated with increased long-term risks for hypertension, type 2 diabetes, and cardiovascular disease.

FDA grants Priority Review to teplizumab for patients aged 1 to 7 years with stage 2 type 1 diabetes to delay stage 3 onset.

Topline data from the phase 3 ATTAIN-MAINTAIN trial evaluated orforglipron for weight maintenance after initial treatment with Wegovy or Zepbound in adults with obesity or overweight.

For patients at high cardiovascular risk with obesity, semaglutide is associated with reduced burden of total hospital admissions.

For patients with hypertension, initiating treatment with an ARB is associated with the best long-term class persistence.

Accelerated linear growth and weight gain from birth to 4 years of age are associated with earlier pubertal onset, particularly in girls.